Literature DB >> 20536348

Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.

Weidong Yu1, Xiaolin Sun, Hongxing Tang, Yunxia Tao, Zonghan Dai.   

Abstract

The expression of p185(Bcr-Abl) in Ba/F3 cells inhibits the chemotactic response of these cells to SDF1alpha. A mutant p185(Bcr-Abl) with deletion of amino acids from 176 to 426 (p185(Delta176-426)) is deficient in suppressing SDF1alpha-stimulated chemotaxis. Comparison of the gene expression profiles among parental Ba/F3 cells and cells transformed by p185(Bcr-Abl) and p185(Delta176-426) reveals that class II phosphoinositide 3-kinase gamma (PI3KC2gamma) expression is markedly down-regulated by p185(Bcr-Abl) but not p185(Delta176-426). Furthermore, knockdown of PI3KC2gamma expression in p185(Delta176-426) cells is sufficient to suppress SDF1alpha-stimulated chemotaxis and to promote infiltration of these cells into the liver. Together, these studies suggest that inhibition of PI3KC2gamma expression may represent a mechanism by which Bcr-Abl suppresses SDF1alpha-induced chemotaxis and induces abnormal homing of leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536348      PMCID: PMC2885034          DOI: 10.3109/10428191003754624

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  30 in total

1.  Are class II phosphoinositide 3-kinases potential targets for anticancer therapies?

Authors:  Colin J Traer; Fiona M Foster; Siemon M Abraham; Michael J Fry
Journal:  Bull Cancer       Date:  2006-05       Impact factor: 1.276

2.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 3.  Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

Authors:  A M Martelli; M Nyåkern; G Tabellini; R Bortul; P L Tazzari; C Evangelisti; L Cocco
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

4.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.

Authors:  D Cortez; L Kadlec; A M Pendergast
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

5.  p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.

Authors:  Jean-Francois Geay; Dorothée Buet; Yanyan Zhang; Adlen Foudi; Peggy Jarrier; Magali Berthebaud; Ali G Turhan; William Vainchenker; Fawzia Louache
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

Review 6.  ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.

Authors:  Michael G Kharas; David A Fruman
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

7.  Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain.

Authors:  H Misawa; M Ohtsubo; N G Copeland; D J Gilbert; N A Jenkins; A Yoshimura
Journal:  Biochem Biophys Res Commun       Date:  1998-03-17       Impact factor: 3.575

8.  cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12.

Authors:  M Rozycka; Y J Lu; R A Brown; M R Lau; J M Shipley; M J Fry
Journal:  Genomics       Date:  1998-12-15       Impact factor: 5.736

9.  Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration.

Authors:  Tania Maffucci; Frank T Cooke; Fiona M Foster; Colin J Traer; Michael J Fry; Marco Falasca
Journal:  J Cell Biol       Date:  2005-05-31       Impact factor: 10.539

10.  Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo.

Authors:  Weidong Yu; Xiaolin Sun; Nancy Clough; Everardo Cobos; Yunxia Tao; Zonghan Dai
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

View more
  1 in total

1.  Targeting PI3K in Cancer: Any Good News?

Authors:  Miriam Martini; Elisa Ciraolo; Federico Gulluni; Emilio Hirsch
Journal:  Front Oncol       Date:  2013-05-08       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.